- Home
- BPT vs BIAF Comparison
BPT vs BIAF Comparison
Compare BPT & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPT
- BIAF
- Stock Information
- Founded
- BPT 1989
- BIAF 2014
- Country
- BPT United States
- BIAF United States
- Employees
- BPT N/A
- BIAF N/A
- Industry
- BPT Integrated oil Companies
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BPT Energy
- BIAF Health Care
- Exchange
- BPT Nasdaq
- BIAF Nasdaq
- Market Cap
- BPT 13.0M
- BIAF 12.2M
- IPO Year
- BPT N/A
- BIAF 2022
- Fundamental
- Price
- BPT $0.61
- BIAF $0.83
- Analyst Decision
- BPT
- BIAF Strong Buy
- Analyst Count
- BPT 0
- BIAF 1
- Target Price
- BPT N/A
- BIAF $6.00
- AVG Volume (30 Days)
- BPT 206.7K
- BIAF 76.9K
- Earning Date
- BPT 03-13-2025
- BIAF 03-31-2025
- Dividend Yield
- BPT N/A
- BIAF N/A
- EPS Growth
- BPT N/A
- BIAF N/A
- EPS
- BPT N/A
- BIAF N/A
- Revenue
- BPT $257,000.00
- BIAF $9,367,785.00
- Revenue This Year
- BPT N/A
- BIAF $285.51
- Revenue Next Year
- BPT N/A
- BIAF $20.05
- P/E Ratio
- BPT N/A
- BIAF N/A
- Revenue Growth
- BPT N/A
- BIAF 2813.87
- 52 Week Low
- BPT $0.40
- BIAF $0.57
- 52 Week High
- BPT $3.20
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- BPT 51.48
- BIAF 52.41
- Support Level
- BPT $0.61
- BIAF $0.75
- Resistance Level
- BPT $0.68
- BIAF $0.85
- Average True Range (ATR)
- BPT 0.05
- BIAF 0.06
- MACD
- BPT 0.01
- BIAF 0.01
- Stochastic Oscillator
- BPT 52.29
- BIAF 87.18
About BPT BP Prudhoe Bay Royalty Trust
BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.